The effect of the combination therapy was higher with anti-CTLA4 than with anti-PD-1, and cumulatively affected 100% of the mice (3/5 CR and 2/5 PR), highlighting that the response needed to be determined as a function of tumor specificities. This evidence concerns the gene CTLA4 and neoplasm.